Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $4.3MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hoffman Michael B | Director | May 20 '26 | Buy | $1.87 | 76,344 | $142,779 | 3,364,883 | May 21 08:11 PM |
| Hoffman Michael B | Director | Apr 02 '26 | Buy | $2.10 | 713,800 | $1,498,980 | 3,288,539 | Apr 03 05:06 PM |
| White Mark K. | Director | Apr 02 '26 | Proposed Sale | $2.08 | 7,142 | $14,848 | — | Apr 02 04:39 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.